SAC Capital Advisors LP, one of the nation’s most successful hedge funds, is a focus of a Securities and Exchange Commission investigation into whether traders used inside information to profit from the $15 billion takeover of biotechnology firm MedImmune Inc. in 2007, people familiar with the matter say.
Read more: SAC Faces Probe of Trading in Biotechnology Firm MedImmune — WSJ.com
